This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Sangamo Gene Therapy Fights HIV

RICHMOND, Calif. ( TheStreet) -- An experimental HIV gene therapy from Sangamo BioSciences (SGMO - Get Report) knocked down the virus to undetectable levels in one patient, according to results from an early stage trial. Five other HIV patients in the same trial, however, did not benefit as much.

Sangamo shares were up 8% to $6.50 in Monday pre-market trading. The stock closed Friday at $6.

The Sangamo gene therapy, known as SB-728, is designed to genetically alter a patient's T cells to eliminate a protein known as CCR5 that is commonly used by HIV to invade and infect cells.

If successful and ultimately approved, the SB-278 gene therapy might be a "functional cure" for HIV, meaning patients would no longer need to take daily regimens of anti-retroviral drugs to keep the virus in check.

Sangamo is still a long way from proving that SB-728 is safe and effective. The data presented Sunday came from a small phase I study in which six HIV patients were infused with the genetically modified T cells and then stopped taking their anti-retroviral drugs for 12 weeks. The study was designed to determine if the modified T cells could take up residence safely in the patients; and then to see if the patients' newly altered immune system could fight off HIV on its own.

Results from the study found a "statistically significant" relationship between the number of genetically modified immune cells in the patients and suppression of viral load, or the amount of HIV in the body.

In one SB-278-treated patient, viral load increased initially after anti-retroviral medicines were stopped. After about six weeks, however, viral loads began falling, a sign that the patient's genetically altered T cells were fighting off HIV. At 12 weeks, the patient's viral load returned to baseline levels and was undetectable.

Further analysis showed that this patient had the highest level of modified T cells in his blood of all the patients enrolled. Importantly, this patient already carried a naturally occurring genetic mutation against the CCR5 protein that gave him a built-in advantage against the virus.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ABT $38.90 0.00%
BMY $72.18 0.00%
GSK $42.91 0.00%
GILD $88.21 0.00%
SGMO $6.30 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs